Miltefosine, the only oral drug approved for the treatment of leishmaniasis—a parasitic
disease transmitted by sandflies—is considered as a success story of research and …

Background The decade following the Regional Strategic Framework for Visceral
Leishmaniasis (VL) elimination in 2005 has shown compelling progress in the reduction of …

Ensuring access to essential medicines for leishmaniasis control is challenging, as
leishmaniasis is a very small and unattractive market for pharmaceutical industry …

Background High frequency of relapse in miltefosine-treated visceral leishmaniasis (VL)
patients in India and Nepal followed up for twelve months. Objective To identify …

Nepal, Bangladesh, and India signed a Memorandum of Understanding (MoU) in 2005 to
eliminate visceral leishmaniasis (VL) as a public health problem from the Indian …

Background To eliminate visceral leishmaniasis (VL) in India and Nepal, challenges of VL
diagnosis, treatment and reporting need to be identified. Recent data indicate that VL is …

Background Visceral leishmaniasis (VL) is among the world's most serious public health
threats, causing immense human suffering and death. In Ethiopia, little is known about the …

Background Reports on the occurrence and outcome of Visceral Leishmaniasis (VL) in
pregnant women is rare in published literature. The occurrence of VL in pregnancy is not …

Antimony (Sb) resistance in leishmaniasis chemotherapy has become one of the major
challenges to the control of this spreading worldwide public health problem. Since the …

Background. For the treatment of visceral leishmaniasis in Bangladesh, single dose
liposomal amphotericin B (ambisome) is supposed to be the safest and most effective …